Enabling Studies Clause Samples
The Enabling Studies clause defines the procedures and permissions for conducting preliminary investigations or assessments necessary before a main project or agreement can proceed. Typically, this clause outlines the scope of studies allowed, such as site surveys, environmental assessments, or technical evaluations, and may specify requirements for notice, access, and reporting. Its core practical function is to ensure that all parties have the necessary information and legal authority to perform due diligence, thereby reducing uncertainty and facilitating informed decision-making before committing to larger obligations.
Enabling Studies. GSK shall have the right at all times during the Research Term and during any relevant Early Development Program Term, exercisable at its sole discretion and its sole cost and expense, to conduct enabling activities such as formulation development, pre-clinical animal studies and/or compound scale-up (“Enabling Studies”) which either GSK or the JSC deems necessary or useful for the purpose of supplementing pre-clinical and/or clinical activities conducted by ChemoCentryx and relating to one or more of the Development Candidates. ChemoCentryx shall offer GSK reasonable cooperation in relation to such enabling activities including, subject to availability, the transfer of quantities of compounds, if necessary. It is understood and agreed by the Parties that any such Enabling Studies are to be conducted by GSK in its sole discretion and not as part of any Early Development Plan or PoC Trial and that ChemoCentryx shall not be required to delay the progress of any Early Development Plan to await the results of any such Enabling Studies.
Enabling Studies. GSK shall have the right at all times during the Research Term, at its own expense, to conduct enabling activities (“Enabling Studies”) which the JSC deems necessary or useful for the purpose of pre-clinical and clinical activities relating to the Pharmacopeia Development Compounds. Pharmacopeia shall offer GSK reasonable cooperation in relation to such enabling activities including, subject to availability, the transfer of quantities of compounds, if necessary.